Q1 2025 Holdings
Filed 2025-05-15 | 35 holdings | $516.8M | 13F-HR/A | View on SEC ↗ · Holdings Table ↗
Amended (2025-05-16) | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Nuvation BIO Inc(NUVB/WS)A | *W EXP 02/10/202 | 67080N119 | $48.1M | 27,330,800 | 9.3% |
| Apellis Pharmaceuticals Inc(APLS)A | COM | 03753U106 | $45.8M | 2,094,000 | 8.9% |
| Dianthus Therapeutics Inc(DNTH)A | COM | 252828108 | $42.5M | 2,341,667 | 8.2% |
| Arrivent Biopharma Inc(AVBP)A | COM | 04272N102 | $38.1M | 2,059,387 | 7.4% |
| Trevi Therapeutics Inc(TRVI)A | COM | 89532M101 | $20.9M | 3,322,000 | 4.0% |
| Centessa Pharmaceuticals PLC(CNTA)A | SPONSORED ADS | 152309100 | $20.5M | 1,425,000 | 4.0% |
| Gossamer BIO Inc(GOSS)A | COM | 38341P102 | $20.2M | 18,350,000 | 3.9% |
| Ocular Therapeutix Inc(OCUL)A | COM | 67576A100 | $17.8M | 2,425,000 | 3.4% |
| Mind Medicine Mindmed Inc(BRD1EUR)A | COM NEW | 60255C885 | $17.7M | 3,018,000 | 3.4% |
| Cogent Biosciences Inc(COGT)A | COM | 19240Q201 | $16.6M | 2,763,000 | 3.2% |
| Kalvista Pharmaceuticals Inc(KALV)A | COM | 483497103 | $15.8M | 1,370,000 | 3.1% |
| Taysha Gene Therapies Inc(TSHA)A | COM SHS | 877619106 | $14.9M | 10,700,000 | 2.9% |
| Taysha Gene Therapies Inc(APGE) | COM SHS | 03770N101 | $14.9M | 10,700,000 | 2.9% |
| Nuvation BIO Inc(NUVB)A | COM CL A | 67080N101 | $13.9M | 7,900,000 | 2.7% |
| Verona Pharma PLC(VRNA)A | SPONSORED ADS | 925050106 | $13.8M | 217,264 | 2.7% |
| Verona Pharma PLC(HUMA) | SPONSORED ADS | 44486Q103 | $13.8M | 217,264 | 2.7% |
| Tourmaline BIO Inc(TRML)A | COM | 89157D105 | $13.8M | 905,000 | 2.7% |
| Merus N VA | COM | N5749R100 | $13.0M | 308,000 | 2.5% |
| Pharvaris N V(PHVS)A | COM | N69605108 | $12.1M | 769,815 | 2.3% |
| Moonlake Immunotherapeutics(MLTX)A | CLASS A ORD | 61559X104 | $11.6M | 296,000 | 2.2% |
| Syndax Pharmaceuticals Inc(SNDX)A | COM | 87164F105 | $11.1M | 904,000 | 2.1% |
| Atyr Pharma Inc(ATYR)A | COM NEW | 002120202 | $10.7M | 3,552,000 | 2.1% |
| Scholar Rock Hldg Corp(SRRK)A | COM | 80706P103 | $10.6M | 329,000 | 2.0% |
| Verastem Inc(IBRX) | COM NEW | 45256X103 | $10.4M | 1,720,000 | 2.0% |
| Verastem Inc(VSTM)A | COM NEW | 92337C203 | $10.4M | 1,720,000 | 2.0% |
| Centessa Pharmaceuticals PLCPut | SPONSORED ADS | G4444H101 | $8.6M | 600,000 | 1.7% |
| Centessa Pharmaceuticals PLC(CNTA)PutA | SPONSORED ADS | 152309100 | $8.6M | 600,000 | 1.7% |
| Regulus Therapeutics Inc(RGLS)A | COM | 75915K309 | $8.1M | 4,637,076 | 1.6% |
| ARS Pharmaceuticals Inc(SPRY)A | COM | 82835W108 | $7.9M | 625,000 | 1.5% |
| Abivax SA(ABVX)A | SPONSORED ADS | 00370M103 | $7.7M | 1,230,000 | 1.5% |
| Erasca Inc(ERAS)A | COM | 29479A108 | $7.0M | 5,136,795 | 1.4% |
| Viridian Therapeutics Inc(VRDN)A | COM | 92790C104 | $6.1M | 450,000 | 1.2% |
| Viridian Therapeutics Inc(CAPR) | COM | 14070B309 | $6.1M | 450,000 | 1.2% |
| Corbus Pharmaceuticals Hldgs(CRBP)A | COM NEW | 21833P301 | $5.9M | 1,115,000 | 1.1% |
| Unicycive Therapeutics IncA | COM | 90466Y103 | $5.7M | 10,000,000 | 1.1% |
| Maze Therapeutics Inc(MAZE)A | COM | 578784100 | $5.2M | 468,000 | 1.0% |
| Perspective Therapeutics Inc(CATX)A | COM NEW | 46489V302 | $4.8M | 2,250,000 | 0.9% |
| Kalaris Therapeutics Inc(KLRS)A | COM | 482929106 | $3.9M | 481,000 | 0.7% |
| Neurogene Inc(NGNE)A | COM | 64135M105 | $3.5M | 303,000 | 0.7% |
| Helix Acquisition Corp IIA | CL A ORD SHS | G4444H101 | $2.8M | 250,000 | 0.5% |